SEC Tracker
Get the app

Zura Bio ZURA

Zura Bio reports $25.82M net loss

Form
10-Q
Filed
Importance
Notable
  1. Net loss of $25.82 million for Q3 2026
  2. Diluted EPS of -$0.62 for Q3 2026
  3. Cash and equivalents at $187.65 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Zura Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$28.77M−$29.32M+1.9%
Net income−$25.83M−$26.3M+1.8%
Operating cash flow−$19K$18.88M−100%
Cash$187.65M$205.13M−8.5%

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Sutro Biopharma STRO public float $60M, Jun 30, 2025
  2. PDS Biotechnology PDSB public float $60M, Jun 30, 2025
  3. iBio IBIO public float $58M, Dec 31, 2025
  4. Medicinova MNOV public float $62M, Jun 30, 2025
  5. Lifevantage LFVN public float $64M, Dec 31, 2025

Data on this page was fetched . The filing on SEC.gov is the record.